Connor, Clark & Lunn Investment Management Ltd. Prelude Therapeutics Inc Transaction History
Connor, Clark & Lunn Investment Management Ltd.
- $18.8 Billion
- Q3 2024
A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Prelude Therapeutics Inc stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 17,293 shares of PRLD stock, worth $15,390. This represents 0.0% of its overall portfolio holdings.
Number of Shares
17,293
Previous 12,345
40.08%
Holding current value
$15,390
Previous $47,000
25.53%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding PRLD
# of Institutions
71Shares Held
35.7MCall Options Held
500Put Options Held
300-
Orbimed Advisors LLC San Diego, CA10.9MShares$9.71 Million0.53% of portfolio
-
Baker Bros. Advisors LP New York, NY10.1MShares$9.01 Million0.22% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.77MShares$3.35 Million0.14% of portfolio
-
Boxer Capital, LLC San Diego, CA1.71MShares$1.52 Million0.19% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD1.1MShares$976,8630.0% of portfolio
About Prelude Therapeutics Inc
- Ticker PRLD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,369,200
- Market Cap $32.4M
- Description
- Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid ...